"Generative AI is prone to produce hallucinations, and incorporating physics-based elements is a key approach to reducing them," commented CASUS. "As the AI-based quantitative phase imaging example ...

BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and ...

Results from a phase 1/2 clinical trial of a novel stem cell treatment for cornea injuries found 14 patients treated and tracked for 18 months had a more than 90% success rate at restoring the ...

MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company that focuses on the development and commercialization of a new molecular synthetic ...

Health Affairs' Senior Deputy Editor Rob Lott interviews Jihye Han of Brigham and Women's Hospital and Harvard University on ...

Q4 2024 Earnings Call Transcript March 3, 2025 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.11 ...

A new stem cell therapy, CALEC, has demonstrated a 92% success rate in regenerating corneas and restoring vision. This ...

We reduced our fair value estimate to $15.50 per share from $27.20 to account for greater headwinds as a newly stand-alone company since its spinoff from Labcorp in 2023, which will weigh on revenue ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

A new computational tool allows researchers to understand how the diverse cell types of the human body are made during ...

A decade after scientists in The Picower Institute for Learning and Memory at MIT first began testing whether sensory stimulation of the brain's 40Hz "gamma" frequency rhythms could treat Alzheimer's ...